Use access key #2 to skip to page content.
$6.35 -0.14 (-2.16%)
5/16/2008 4:00 PM

Exelixis, Inc. (EXEL)

CAPS Rating:
*****

A development-stage biotechnology company dedicated to the discovery and development of novel small molecule therapeutics for the treatment of cancer and other serious diseases.

View All Commentary (EXEL)

Recs

11

Avatar ResearchLover (98.29) Submitted: 3/12/08 12:11 PM : Outperform Start Price: $5.29 EXEL Score: 12.73

I am a molecular biologist and have been at presentations for mid/late stage compounds, such as PPAR ligands, that EXEL is developing. They have the expertise to develop successful compounds. And they are at a bargain basement price now. If you need a signal to enter, wait for insider buying, which hasn't occured lately as of 3/10/08.

Report this Post Replies: 0 | Reply

Featured Broker Partners